Hepatitis B Virus News and Research

RSS

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report.

9 Feb 2016

World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

Rock-icon David Bowie died recently at the age of 69 after a battle with what is being reported as liver cancer. Each year, more than 800,000 people die from liver cancer globally, the second biggest cancer killer. Yet, a high majority of these deaths are completely preventable.

5 Feb 2016

UC Davis researchers develop Hepatitis virus-like particles to target breast cancer

UC Davis researchers have developed a way to use the empty shell of a Hepatitis E virus to carry vaccines or drugs into the body. The technique has been tested in rodents as a way to target breast cancer, and is available for commercial licensing through UC Davis Office of Research.

4 Feb 2016

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Bristol-Myers Squibb today announced that the European Commission has approved the expanded use of Daklinza, a first-in-class oral, once-a-day pill used in combination with other treatments as an option for adult patients with chronic hepatitis C virus infection who are co-infected with HIV or who have had a prior liver transplant.

30 Jan 2016

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.

29 Jan 2016

Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Serum hepatitis B core-related antigen could serve as a quantitative marker of response to pegylated interferon therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen (HBeAg), findings indicate.

26 Jan 2016

Rescue TDF monotherapy effective in multidrug resistant chronic HBV

Researchers from the Republic of Korea say that rescue therapy with tenofovir disoproxil fumarate alone is an appropriate option for patients with multidrug resistant chronic hepatitis B virus infection.

26 Jan 2016

STAT4 variant predicts HBV IFNα response

Variation in the STAT4 gene is associated with response to interferon (IFN)α therapy in patients with hepatitis B e antigen-positive chronic hepatitis B virus infection, suggests research published in Hepatology.

26 Jan 2016

Only 17.4% of nurses comply with all nine standard precautions for infection prevention

Only 17.4 percent of ambulatory care nurses reported compliance in all nine standard precautions for infection prevention, according to a study published in the January issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

21 Jan 2016

Study outlines new model to help predict age-related response to hepatitis B vaccine

Physicians have known for years that patients respond differently to vaccines as they age. There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine.

20 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

Inflammation associated with elevated glutamate in the brain could guide depression treatments

Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine.

13 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Hepatitis C virus linked to increased risk of developing Parkinson's disease

The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the December 23, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.

24 Dec 2015

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy.

22 Dec 2015

AGA issues six new clinical practice guidelines

In 2015, the American Gastroenterological Association issued six clinical practice guidelines, all published in AGA's official journal Gastroenterology, offering current, evidence-based point-of-care recommendations to guide physicians at the bedside.

17 Dec 2015

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus.

16 Dec 2015

SLU scientist awarded new $2.2 million NIH grant to develop cure for hepatitis B

With proof-of-principle in his pocket and a new $2.2 million grant from the National Institutes of Health, SLU scientist John Tavis, Ph.D., will take his 25 year mission to finally develop a cure for the hepatitis B virus into the next phase.

15 Dec 2015

Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

In its commitment to provide diagnostic insights that enhance patient care and outcomes, Quest Diagnostics will automatically perform molecular testing on all patient specimens whose antibody screening results indicate hepatitis C virus infection, and remove standalone positive antibody screening as a test option.

From Quest Diagnostics 8 Dec 2015

HBsAg may persist in chronic HBV patients beyond seroclearance

The use of a highly sensitive assay for the detection of hepatitis B surface antigen suggests that HBsAg negativity as evaluated by the conventional test may not be indicative of seroclearance in patients with chronic hepatitis B virus infection.

3 Dec 2015

Hepatitis B Virus News and Research

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

UC Davis researchers develop Hepatitis virus-like particles to target breast cancer

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Rescue TDF monotherapy effective in multidrug resistant chronic HBV

STAT4 variant predicts HBV IFNα response

Only 17.4% of nurses comply with all nine standard precautions for infection prevention

Study outlines new model to help predict age-related response to hepatitis B vaccine

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Inflammation associated with elevated glutamate in the brain could guide depression treatments

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Hepatitis C virus linked to increased risk of developing Parkinson's disease

Roche announces availability of cobas HBVassay for use on cobas 4800 System

AGA issues six new clinical practice guidelines

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

SLU scientist awarded new $2.2 million NIH grant to develop cure for hepatitis B

Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

HBsAg may persist in chronic HBV patients beyond seroclearance

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News